Stocks
Keros Therapeutics, Inc.KROS
NASDAQHealthcareBiotechnology$11.35
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapeutics targeting the TGF-beta superfamily to treat hematological and musculoskeletal disorders. Its lead product candidate, KER-050, is in Phase 2 trials for myelodysplastic syndromes and myelofibrosis, with additional programs in pulmonary arterial hypertension. Investors track the stock for its pipeline catalysts and potential in high unmet need indications.
52W Range: $9.69-$22.55
Congressional Interest in Keros Therapeutics, Inc. (KROS)
No congressional trades have been disclosed for Keros Therapeutics, Inc. (KROS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading KROS?
No congressional trades found for this stock.